Trial Profile
Phase Ib Trial of Intratumoral Injection of a Recombinant Canarypox Virus Encoding Human B7.1 (ALVAC-hB7.1) [ALVAC CEA] or a Combination of ALVAC-hB7.1 and a Recombinant Canarypox Virus Encoding Human Interleukin 12 (ALVAC-hIL-12) in Patients With Surgically Incurable Melanoma.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs ALVAC CEA (Primary) ; ALVAC hIL 12 (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 03 Nov 2005 New trial record.